Castrate Resistant Prostate Cancer (CRPC) is a difficult entity to treat in the spectrum of prostate cancer disease. Recently, Follicle Stimulating Hormone (FSH) has been shown to play an important part in the natural history of prostate cancer disease progression (Crawford et al. , 2014). Here, we discuss a now deceased 94 year-old patient who illustrates the importance of this.
Urology case reports. 2016 Apr 24*** epublish ***
Salvatore Catarinicchia, E David Crawford
University of Colorado, Division of Urology, 12631 E. 17th Avenue, C-305, Aurora, CO 80045, USA., University of Colorado, Division of Urology, 12631 E. 17th Avenue, C-305, Aurora, CO 80045, USA.